Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced HER2-positive Breast Cancer or Gastric Cancer
Interventions: DRUG: LJM716|DRUG: Trastuzumab
Sponsor: Novartis Pharmaceuticals